Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$0.62 ▼ -0.06
(-9.13%)
MKT CAP: $1.3M • VOL: 140.0K
52W L $1 52W H $68
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
VBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $780.0K | $1.2M |
| YoY Revenue Growth % | — | -33.7% | — |
| Gross Profit | — | $2.0K | — |
| Gross Margin % | — | 0.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.9M | -$4.5M | -$8.2M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$8.9M | -$5.7M | -$8.2M |
| EBITDA (Normalized) | -$7.9M | -$4.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.0M | -$5.7M | -$8.5M |
| Capital Expenditures (CapEx) | $38.0K | $0 | — |
| Free Cash Flow (FCF) | -$7.0M | -$5.7M | -$8.5M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $12.6M | $2.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $16.8M | $2.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VBIO.